Looking at the patents, GTG seem to have some good protection around polygenic risk scoring and treatment of breast cancer, and the computer systems patent could possibly occupy an important or annoying space for another company to consider buying out. The covid patents seem to be old news already, and not sure about the surgical sampling patents, would be nice to see some more patents around other therapeutic areas for PRS. If this sector is going to take off, GTG may be a cheap bet for someone to take. As a shareholder, I live in hope...
GTG Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held
